March 16 (Reuters) - CytomX Therapeutics Inc CTMX.O:
CYTOMX’S VARSETATUG MASETECAN (EPCAM PROBODY® ADC) CONTINUES TO DEMONSTRATE POSITIVE DATA SUPPORTING POTENTIAL AS A NEW TREATMENT OPTION IN LATE-LINE COLORECTAL CANCER
CYTOMX THERAPEUTICS INC - PHASE 1 STUDY WITH BEVACIZUMAB INITIATED; PHASE 1B/2 CHEMOTHERAPY COMBINATION STUDY TO START BY END 2026